3Z-20-003

**3Z-20-003** is a repurposed **small molecule** **L-type calcium channel blocker** developed by **3Z Pharmaceuticals** (also referred to as 3Z ehf) for **attention deficit hyperactivity disorder (ADHD)**. It has demonstrated proof-of-concept in **zebrafish** behavioral screening models and **rodent** models, as well as supportive **in silico** data, positioning it as a candidate for neurological indications via the **505(b)(2) NDA** pathway in the US and **Article 8(3)/10** in the EU. The drug targets **L-type calcium channels**, which play a critical role in neuronal excitability and signaling, potentially offering a novel mechanism for ADHD treatment.

Other names

3Z 20 003